NLX-P101 (Cornell University)

N/A

Report date: 2023/10/26 16:21:01

Base Information

Drug NameNLX-P101 (Cornell University)
Drug Alias NameGAD gene therapySTN AAV-GAD gene therapyNLX-P-101AAV-GADNLX-P101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGlutamate decarboxylase gene transference
TargetsGlutamate decarboxylase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued
Highest Status in ChinaN/A
Originator CompaniesNeurologix IncCornell University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeurologix IncHologen Neuro AI LtdCornell University
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A